0001062993-23-001325.txt : 20230124
0001062993-23-001325.hdr.sgml : 20230124
20230124160733
ACCESSION NUMBER: 0001062993-23-001325
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230120
FILED AS OF DATE: 20230124
DATE AS OF CHANGE: 20230124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GUIFFRE CHRISTOPHERD T
CENTRAL INDEX KEY: 0001219021
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39969
FILM NUMBER: 23548219
MAIL ADDRESS:
STREET 1: 65 HAYDEN AVE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pear Therapeutics, Inc.
CENTRAL INDEX KEY: 0001835567
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000]
IRS NUMBER: 854103092
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 STATE STREET
STREET 2: 13TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02109
BUSINESS PHONE: 6469322774
MAIL ADDRESS:
STREET 1: 200 STATE STREET
STREET 2: 13TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02109
FORMER COMPANY:
FORMER CONFORMED NAME: Thimble Point Acquisition Corp.
DATE OF NAME CHANGE: 20201208
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2023-01-20
0001835567
Pear Therapeutics, Inc.
PEAR
0001219021
GUIFFRE CHRISTOPHERD T
C/O PEAR THERAPEUTICS, INC.
200 STATE STREET, 13TH FLOOR
BOSTON
MA
02109
0
1
0
0
CFO, COO, Treas., & Asst. Sec.
Class A Common Stock
2023-01-20
4
S
0
19540
1.13
D
29960
D
The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $1.03 to $1.335, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
/s/ Stacie S. Aarestad, Attorney-in-Fact
2023-01-24